NCT01949766No Longer Available不适用
Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 6 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Byler Disease
- •Cholestasis
- •Tolerance of Buphenyl therapy
排除标准
- •Allergy/Hypersensitivity to RAVICTI
研究者
相似试验
已完成
4 期
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT00078338EMD Serono764
已完成
不适用
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyMultiple Sclerosis, Relapsing-RemittingNCT01141751Merck KGaA, Darmstadt, Germany334
招募中
不适用
Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)Radiotherapy Side EffectALK Gene MutationNon-small Cell Lung CancerNCT05724004Karolinska University Hospital70
终止
4 期
Raptiva in Palm and Sole PsoriasisChronic Plaque PsoriasisNCT00972543Merck KGaA, Darmstadt, Germany6
已完成
2 期
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis BHepatitis BNCT00128544Novartis130